Heterogeneous hybrid immunity against Omicron variant JN.1 at 11 months following breakthrough infection.

Publication date: Jul 19, 2024

Concepts	Keywords
Breakthrough	Antibodies, Viral
Infection	Antibodies, Viral
Months	Breakthrough Infections
Omicron	COVID-19
Target	Female
	Humans
	Male
	SARS-CoV-2
	Spike Glycoprotein, Coronavirus
	Spike Glycoprotein, Coronavirus

Type	Source	Name
disease	MESH	breakthrough infection
pathway	REACTOME	Signal Transduction
disease	MESH	COVID 19
disease	VO	vaccination
disease	MESH	infection
disease	VO	population
disease	VO	vaccinated
disease	MESH	reinfection
disease	VO	immunization
disease	IDO	history
disease	IDO	blood
drug	DRUGBANK	Dimercaprol
disease	VO	titer
disease	VO	unvaccinated
disease	VO	efficient
disease	IDO	susceptibility
disease	VO	vaccine
drug	DRUGBANK	Coenzyme M
drug	DRUGBANK	Guanosine
disease	IDO	process
disease	VO	time
disease	VO	ANOVA
drug	DRUGBANK	Proline
disease	MESH	Breakthrough Infections COVID-19
disease	VO	Glycoprotein

(Visited 2 times, 1 visits today)